Patent Unpending?

India should overturn its August decision to grant Pfizer a patent on its pneumonia vaccine Prevnar13 (PCV13), Médecins Sans Frontières is arguing in a Delhi court today.

The patent blocks India’s vaccine manufacturers from developing and marketing PCV13 until 2026, and the lives of countless children hang in the balance. “The decision to give Pfizer a patent in India for this vaccine is unmerited and just a way for them to remain the only game in town by blocking more affordable pneumonia vaccines,” said Kate Elder of MSF’s Access Campaign.

MSF says high prices are the main reason pneumonia vaccines haven’t been introduced in standard vaccination packages for about a third of countries.

MSF

Secondary Topic
Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top